��«����Ƶ

cliexa® Partners with the ��«����Ƶ's Cognitive and Affective Neuroscience Lab (CANLab) for Multidimensional Pain Tracking and Predictive Analytics Research.

cliexa, Inc., which offers a suite of mobile platforms for chronic disease management, announces its collaboration with CU ��«����Ƶ’s CANLab and Institute of Cognitive Science (ICS). cliexa will collaborate with CANLab’s team, headed by Professor Tor Wager, as they lead in multidimensional pain tracking and predictive analytics research.

CU ��«����Ƶ jointly filed a provisional patent with cliexa for the multidimensional objective pain concept with CANLab. The CANLab focuses on identifying a particular pattern of brain activity, which is diagnostic of physical pain. cliexa-Ease’s mobile platform hosts the research concept and is being used to further develop CANLab’s existing pain studies. cliexa-Ease will deliver an exclusive pain assessment model, which, in collaboration with CU ��«����Ƶ, anticipates commercialization by mid 2018.

Mehmet Kazgan, founder and CEO of cliexa, explains how they are excited about the partnership with Wager’s CANLab because of its “leading research studies for multidimensional pain tracking.” He also describes how “working with neuroscientists at ��«����Ƶ is taking [the cliexa platform] to the next level of objectifying patient outputs with multiple reference points.”

Professor Wager highlights how the collaboration will “expand our ability to understand how emotion affects pain in daily life.” Dr. Pavel Goldstein, the scientific lead of the project, adds the partnership will provide both “an incredible opportunity to establish a platform for researching chronic pain conditions” and “important feedback to pain patients and their clinicians with unique information about patient health.”

Cognitive and Affective Neuroscience Lab

Professor Tor Wager leads CANLab, which is housed by CU ��«����Ƶ’s Institute of Cognitive Science (ICS) and the Psychology and Neuroscience Department. CANLab uses machine-learning to develop fMRI-based biomarkers for clinically relevant outcomes, such as pain. It subsequently tests how psychological factors influence these biomarkers. The lab also engages in collaborative, translational research, which incorporates brain systems-level analyses into the study of clinical disorders, including PTSD, depression, schizophrenia, and chronic pain. 

Learn more about the CANLab at 

cliexa
The mobile platform technology developed by cliexa enables patients to track their chronic disease activity by quantifying symptoms using scientifically-proven and clinically-validated scoring models. cliexa delivers quantified disease activity and medication adherence through patient reported outcomes through real-time integration to electronic medical records, which streamline processes and increase efficiency in population health management.

Learn more about cliexa at